Lawson William E
Division of Cardiology, State University of New York, Health Sciences Center, Stony Brook, New York 11794, USA.
Clin Cardiol. 2002 Dec;25(12 Suppl 2):II16-21. doi: 10.1002/clc.4960251406.
Most patients who receive enhanced external counterpulsation (EECP) have symptomatic coronary artery disease. These patients have either responded poorly to pharmacologic therapy or are poor candidates for revascularization procedures. Such patients receive a variety of consistent benefits from EECP treatment. As more is learned about EECP, patients once excluded from early clinical trials are now able to take advantage of EECP. Nevertheless, EECP is not suitable for some patients. It has a favorable adverse event profile for most patients undergoing the treatment. Medicare reimbursement coverage limitations remain an obstacle to having a broad cross-section of patients benefit from EECP.
大多数接受增强型体外反搏（EECP）治疗的患者患有症状性冠状动脉疾病。这些患者要么对药物治疗反应不佳，要么不适合进行血运重建手术。此类患者从EECP治疗中获得了多种持续的益处。随着对EECP了解的增多，曾经被排除在早期临床试验之外的患者现在能够受益于EECP。然而，EECP并不适合所有患者。对于大多数接受该治疗的患者而言，其不良事件情况良好。医疗保险报销覆盖范围的限制仍然是阻碍广大患者群体从EECP中受益的一个障碍。
